Strategic Plan

SITC's Strategic Plan

Leading the next wave of immuno-oncology discovery for patients.

#SITCquestfor100

Strategic Plan 2024-2026
The Quest to 100 Novel Agents by 2034

With six transformative, innovative, and diverse strategic goals, SITC set a vision for 100 novel immuno-oncology agents approved by 2034. Join us as we leverage our strategic goals to develop a diverse portfolio of agents, expand into earlier lines of therapy, explore AI solutions, and broaden our community tent.

The Next Wave of Immuno-oncology:
A Roadmap from the Society for Immunotherapy of Cancer

This Journal for ImmunoTherapy of Cancer (JITC) Special Series will outline the current state of the field, elevate the most pressing challenges, and propose the most promising opportunities for high clinical impact in the scientific, clinical, and regulatory arenas of cancer immunotherapy. 

SITC's Diverse Strategic Goals and Initiatives

Education and Scientific Exchange

Providing critical education on state-of-the-art drug development and business development strategies, with unique opportunities for scientific exchange among academia, biotech, pharma, venture capital, government agencies and patient advocates.

Initiatives

Immuno-oncology Drug Development Summit

Beyond Checkpoint Inhibitors: New Immuno-oncology Modalities and Approaches

Professional Standards

Setting the standards for the field with additional focus on data curation and sharing to enable AI optimization today and for the future.

Initiatives

AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series

Definitions, End Points, and Clinical Trial Designs for Bladder Cancer

Intratumoral Immunotherapy Clinical Trial Design

Immune Engineering Workshop: Building Bridges Between All Aspects of Engineering and Immuno-oncology

Global Access and Impact

Collaborating strategically to expand global reach to SITC resources and increase immuno-oncology access to diverse populations worldwide.

Initiatives

Increasing Access to IO: A Global Webinar Series

Low- to Lower-Middle Income Economies Access Program

Expanding Access to Cellular & Bispecific Therapies

Policy and Advocacy

Engaging the multi-stakeholder community in critical regulatory discussions, from surrogate endpoints to release criteria and novel digital pathology technologies.

Initiatives

Release Criteria Summit — Coming Soon!

Surrogate Endpoints Consensus Meeting Summary — Coming Soon!

Hill Visits

Science and Research

Advancing the latest research on the development of novel constructs, immuno-prevention and premalignant strategies, and identification of new targets and pathways.

Initiatives

Immunomodulation of ADCs

Summit on Intralesional Immunotherapy: Moving Beyond Oncolytic Viruses

Targets for Cancer IO: A Deep Dive Series

Glyco-Immunology Webinar Series

2025 Spring Scientific

Leadership Development

Adapting and expanding leadership development initiatives to include new career pathways in biotech, pharma, venture capital, and beyond.

Initiatives

Early Career Scientist Speed Mentoring Event

Expert Panel Listening Sessions

Manuscripts

Challenges and Opportunities in Cancer Immunotherapy: A Society for Immunotherapy of Cancer (SITC) Strategic Vision

Manuscripts 2-5
Coming soon


Join Us On Our Quest

The SITC community believes that there is more innovation to be created, more transformations to be attained, and more achievements to be realized. In short, our work is not done. Join us as we leverage our strategic goals to develop a diverse portfolio of agents, expand into earlier lines of therapy, explore AI solutions, and broaden our community tent.

Join the SITC Family

#SITCQuestfor100